Humanigen to Present at the 2021 LD Micro Invitational XI
June 03 2021 - 8:00AM
Business Wire
Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage
biopharmaceutical company focused on preventing and treating an
immune hyper-response called ‘cytokine storm’ with its lead drug
candidate, lenzilumab, today announced it will present at the 2021
LD Micro Invitational XI, held virtually from June 8- 10, 2021.
LD Micro is host to some of the most influential conferences in
the small-cap world. Humanigen has been selected to participate in
the first day of the conference, during the “Hall of Fame” session,
which highlights some of the top performers since the LD Micro
conference began in 2008.
Management will discuss its lead product, lenzilumab, which has
been submitted for Emergency Use Authorization (EUA) to the U.S.
Food and Drug Administration, in addition to providing an update on
the Company’s launch preparation efforts for lenzilumab, and an
overview of the Company’s other development programs.
Details for the upcoming event are below:
2021 LD Micro Invitational XI
Date: Tuesday, June 8, 2021 Time: 12:00 PM ET
Link:
https://zoom.us/w/97887030243?tk=E8Tl4eGWx6OkFEz1kDcoG5RSyGTAqm9RooTXrmIW7MA.DQIAAAAWyoWL4xYtb21WVVg1eFN4dUNURjJHUC05ckhRAAAAAAAAAAAAAAAAAAAAAAAAAAAA&pwd=TGFoRnVjdzNQQ1NmMlBJNXF1aVgvdz09
About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and
pre-clinical therapies for the treatment of cancers and infectious
diseases via its novel, cutting-edge GM-CSF neutralization and
gene-knockout platforms. Humanigen’s immediate focus is on the
development of lenzilumab as a therapy for hospitalized, hypoxic
COVID-19 patients. Humanigen recently announced plans to initiate a
randomized, multicenter, potentially registrational, Phase 2 study
to evaluate the efficacy and safety of lenzilumab combined with all
commercially available CD19 CAR-T therapies in diffuse large B-cell
lymphoma.
Humanigen is also focused on creating next-generation
combinatory gene-edited CAR-T therapies using strategies to improve
efficacy while employing GM-CSF gene knockout technologies to
control toxicity. In addition, Humanigen is developing its own
portfolio of proprietary first-in-class EphA3-CAR-T for various
solid cancers and EMR1-CAR-T for various eosinophilic disorders.
Humanigen is also exploring the effectiveness of its GM-CSF
neutralization technologies (either through the use of lenzilumab
as a neutralizing antibody or through GM-CSF gene knockout) in
combination with other CAR-T, bispecific or natural killer (NK) T
cell engaging immunotherapy treatments to break the
efficacy/toxicity linkage, including to prevent and/or treat
graft-versus-host disease (GvHD) in patients undergoing allogeneic
hematopoietic stem cell transplantation (HSCT). For more
information, visit www.humanigen.com and follow Humanigen on
LinkedIn, Twitter and Facebook.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment, and expectations regarding future
performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct, and
you should be aware that actual events or results may differ
materially from those contained in the forward-looking statements.
Words such as "will," "expect," "intend," "plan," "potential,"
"possible," "goals," "accelerate," "continue," and similar
expressions identify forward-looking statements, including, without
limitation, statements regarding the timing for submission of
applications for EUA and BLA, and for conditional marketing
authorization in the UK and EU, as well as statements regarding
Humanigen’s beliefs relating to the technologies in Humanigen’s
current pipeline.
Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to, the risks inherent in
the company’s lack of profitability and potential need for
additional capital to grow its business; its dependence on partners
to further the development of its product candidates; the
uncertainties inherent in the development, attainment of the
requisite regulatory authorizations and approvals and launch of any
new pharmaceutical product; the outcome of pending or future
litigation; and the various risks and uncertainties described in
the "Risk Factors" sections and elsewhere in Humanigen's periodic
and other filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not rely upon any
forward-looking statements as predictions of future events. The
company undertakes no obligation to revise or update any
forward-looking statements made in this presentation to reflect
events or circumstances after the date hereof, to reflect new
information or the occurrence of unanticipated events, to update
the reasons why actual results could differ materially from those
anticipated in the forward-looking statements, in each case, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210603005546/en/
Humanigen Media Grace Catlett RXMD Gcatlett@rxmedyn.com
516-318-8563
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024